The First Live Birth in Lithuania After Application of Preimplantation Genetic Testing

Živilė Gudlevičienė*
Vilnius University Hospital Santaros Klinikos, Division of Fertility Technologies and Germ Cell Bank, Vilnius, Lithuania
Vilnius University, Faculty of Medicine, Vilnius, Lithuania

Raminta Baušytė
Vilnius University Hospital Santaros Klinikos, Clinic of Obstetrics and Gynaecology, Santaros Fertility Center, Vilnius, Lithuania
Vilnius University, Life Sciences Center, Vilnius, Lithuania

Evelina Dagytė
Vilnius University Hospital Santaros Klinikos, Center for Medical Genetics, Vilnius, Lithuania
Vilnius University, Faculty of Medicine, Vilnius, Lithuania

Danutė Balkelienė
Vilnius University Hospital Santaros Klinikos, Center for Medical Genetics, Vilnius, Lithuania

Algirdas Utkus
Vilnius University, Faculty of Medicine, Vilnius, Lithuania

Diana Ramašauskaitė
Vilnius University Hospital Santaros Klinikos, Clinic of Obstetrics and Gynaecology, Vilnius, Lithuania
Vilnius University, Faculty of Medicine, Vilnius, Lithuania

Summary. Background. Preimplantation genetic testing (PGT) is a genetic testing procedure that is performed before the implantation of embryos for the identification of genetic abnormalities. It is commonly performed when one or both expecting parents have such abnormalities and are at a high risk of passing them to their offspring. The aim of this case report is to describe the first successful IVF/ICSI/PGT procedure in Lithuania.

Case report. A 27-year-old woman and a 31-year-old man, a married couple, were referred to VUHSK Santaros Fertility Center after trying to conceive for 4 years. In a previous relationship, the woman got pregnant spontaneously and decided to terminate the pregnancy. The husband does not have any children. During the medical examination, the transvaginal ultrasound revealed a low antral follicle count and low anti-Müllerian hormone level for the woman. Semen analysis for the male patient showed severe oligoasthenospermia, which confirmed the previous abnormal spermogram results. Chromosome analysis revealed normal karyotype for the woman (46,XX) and Robertsonian translocation for the husband (45,XY,der(13;14)(q10;q10)). After the interdisciplinary medical team counselling, an ICSI with PGT-SR was suggested for the couple. The woman underwent controlled ovarian hyperstimulation with GnRH antagonist protocol for 11 days. Only one...
embryo with no unbalanced rearrangements was identified and transferred to the woman. On the 14th day post oocyte retrieval, the first serum β-hCG result was received – 39.5 mIU/ml, and the normal gestational sac at 5 weeks and 3 days was confirmed by ultrasound examination.

**Conclusion:** the first successful pregnancy was achieved in Lithuania and the first IVF/ICSI/PGT-SR newborn in Lithuania was born in 2019 – a vaginal birth of a healthy girl with gestational age of 38 weeks and 4 days and a weight of 2820 g; the Apgar score was 10/10. The IVF/ICSI/PGT procedure was successfully implemented by the multidisciplinary team in VUHSK.

**Keywords.** Assisted reproductive technologies, Preimplantation genetic testing, Robertsonian translocation, Intracytoplasmic sperm injection, Embryo biopsy

---

**Introduction**

Preimplantation genetic testing (PGT) is a genetic testing procedure that is performed before the implantation of early stage (2-5 days after fertilization in the laboratory) embryos to identify genetic rearrangements and select the best one(s) for the embryo transfer [1, 2]. PGT is divided into PGT for aneuploidies (PGT-A), PGT for monogenic/single gene defects (PGT-M), and PGT for chromosomal structural rearrangements (PGT-SR) [3, 4, 5]. PGT-A is performed for couples of advanced maternal age, or histories of recurrent miscarriage and repeated implantation failure. PGT-M is performed for couples with confirmed monogenic hereditary diseases and when monogenic disease has already been detected in one of family's children. PGT-SR is commonly performed when one or both partners have genetic chromosomal rearrangements and are at a high risk of passing them on to their offspring [6, 7].
In Lithuania, first IVF (in vitro fertilization) babies were born in 1994 after “medical tourism” to United Kingdom. The first private clinics were established and the first IVF procedure was performed in Lithuania in 1998 [8]. For a long time, only private IVF clinics have existed in Lithuania with a limited number of cycles due to the lack of a Law for Assisted Reproduction and governmental reimbursement for IVF to couples. According to the Act of legislation of the Ministry of Health (1999), any invasive procedure and research on embryos were prohibited. The Law for Assisted Reproduction was accepted by the Lithuanian Parliament in 2016; the invasive PGT procedures on embryos of genetically screened couples with high risk of passing severe genetic disorders to their offspring was included. The first University Hospital IVF center in Vilnius, the University Hospital Santaros Klinikos (VUHSK) with multidisciplinary genetic counselling for couples and PGT for embryos at the Center for Medical Genetics (CMG) was also established in 2016. The first PGT in VUHSK was performed in 2017, however, the first successful pregnancy and live birth after PGT was achieved in 2019.

Case report

Couple investigation. A 27-year-old woman and her 31-year-old husband attended VUHSK the Centre of Obstetrics and Gynecology (COG) Santaros Fertility Center (SFC) in September 2018 with a referral by a gynecologist due to the male’s infertility after trying to conceive for 4 years. In a previous relationship, the woman got pregnant spontaneously, but decided to terminate the pregnancy. The husband had no children. Patients were informed about scientific impact of this case, asked to sign a VUHSK confirmed Informed Consent for the publication of results, and they signed it.

During the medical examination of the infertile couple in VUHSK COG SFC, unfavorable results for conception were found. First of all, the transvaginal ultrasound for the woman revealed a low antral follicle count of 7 (3 on the right ovary and 4 on the left ovary) on the third menstrual cycle day, and her anti-Müllerian hormone (AMH) level was 0.78 ng/ml, also. These clinical criteria predicted probable poor ovarian response. Interestingly, the woman did not have any known risk factors for diminished ovarian reserve and was of a young reproductive age. Additionally, she was diagnosed with hypothyroidism due to high thyroid-stimulating hormone (TSH) level – 4.785 mU/l. So, levothyroxine treatment was started immediately after the endocrinologist consultation. Other laboratory and instrumental examination results were without pathologies.

For the man, abnormal semen analysis results were observed in a few recent years: oligoastenospermia (in January 2016; sperm count – 6x10⁶/ml, progressively motile spermatozoa – 33%), oligoastenoteratospermia (in February 2016; sperm count – 4x10⁶/ml, progressively motile spermatozoa – 25%), azoospermia (in July 2018). Due to these results he was advised by a urologist to receive hormonal treatment, but it had no effect. After the performing of a sperm test in the VUHSK OGC Division of Fertility Technologies and Germ Cell Bank, the husband was diagnosed with severe oligoastenospermia: sperm cell count was 1x10⁶/ml, only immotile spermatozoa were found. All sperm analysis were evaluated according to the World Health Organization reference 2010 [9, 10].

The couple was referred to genetic counselling. Chromosome analysis of G banded metaphases showed normal female karyotype for the woman (46,XX) and male karyotype with balanced chromosomal rearrangement – Robertsonian translocation between 13 and 14 chromosomes for the man (45,XY,der(13;14)(q10;q10)) (Figure 1).

After interdisciplinary medical team counselling, an IVF procedure with intracytoplasmic sperm injection (ICSI) to be followed by PGT-SR for embryos was suggested.

Ovarian stimulation and oocyte retrieval. IVF stimulation cycle was started for the woman with TSH concentration <2.5 mU/l. After that, on the third menstrual cycle day, she underwent
controlled ovarian hyperstimulation with GnRH antagonist stimulation protocol with dose of 300 IU/day of recombinant follicle stimulating hormone (FSH) for 11 days. When the largest follicles reached ≥18 mm, recombinant human chorionic gonadotropin (hCG), a dose of 10000 IU, was provided and 36 h later the transvaginal oocyte retrieval was performed. A total of 13 oocytes were collected, and mature oocytes (in metaphase II) were injected, resulting in viable embryos. After the oocyte retrieval procedure, the luteal phase support with appropriate medications was started.

Embryos cultivation. On the day of IVF under controlled ultrasound ovarian puncture using local anaesthesia 13 oocytes were aspirated and directly transferred into FertiCult IVF medium (FertiPro, Belgium). The oocytes were incubated until the processing in 5.5% CO2 and 37°C incubator (Astec, Japan). 4 hours after aspiration, the oocytes were prepared for ICSI procedure: denuded using 135 mikrom Denuding pipette (Gynetics, Belgium) and 10% Hialuronidase (FertiPro, Belgium). After denudation, only 8 methaphase II (MII) oocytes were injected under an inverted Nikon Eclipse Ti microscope (Nikon, Japan) using RI Integra TM 3 micromanipulator (Research Instruments, UK) and 35° Injection and 35° Holding micropipettes (Reproline, Germany). 6 out of 8 injected oocytes were fertilized after ICSI: the two-pronucleus stage was stated 24 hours after the ovarian puncture. Embryos were cultivated in 50 mikrol drops in the one step SAGE medium (Origio, Denmark) under the mineral oil (Irvine Scientific, USA). On day 3 of the embryo development (3-6 blastomere stage, Figure 2 A, B, C, D), the embryo biopsy using RI Saturn laser (Research Instruments, UK), 50 mikrom Biopsy pipettes (Reproline, Germany) and RI Integra TM 3 micromanipulator (Research Instruments, UK) was performed. RI Viewer program (Research Instruments, UK) was used to select and cut the single blastomere (Figure 2 E). The single blastomere was transferred into the 0.2 ml microtubes and directly transported on ice to the VUHSK CMG.

Genetic analysis of the embryos. In the CMG, genetic chromosomal analysis of the embryos was performed by Next Generation Sequencing (on the Ion PGM™ System, Life Technologies, USA) using The Ion ReproSeq™ PGS View Kits (PGT-SR) (Life Technologies, USA). The method is based on whole genome amplification and low-pass whole genome next generation sequencing to detect chromosomal aneuploidies, unbalanced chromosome arm events (>48 Mb) from a single cell.

Four embryos were analysed. Three embryos (1st, 3rd and 4th) showed a chaotic chromosomal constitution. One embryo (2nd) had a normal diploid karyotype with a 46,XX karyotype without any unbalanced chromosome rearrangements >48 Mb (Figure 3). The median absolute pairwise difference (MAPD) value was 0.210. MAPD is an estimate of coverage variability between adjacent genomic tiles. The productive reads count of a low-pass whole genome next generation sequencing was 128 610. The copy number variation (CNV) call at a MAPD <0.300 and the productive reads

Figure 1. Normal female karyotype (A), male karyotype with Robertsonian translocation (indicated by arrow) (B).
count >100 000 are classified as accurate. The PGT-SR analysis result of the 2nd embryo was normal. The diploid 2nd embryo was transferred to the uterus.

**Embryo transfer.** After performing PGT-SR, only one embryo with no unbalanced chromosomal rearrangements (embryo No 2, see Figure 2 B) was identified and transferred to the woman on day 5 (Figure 2 F) using Cook Access Nano embryo transfer catheter (Cook, USA).

**Pregnancy and baby birth.** On the 14th day post oocyte retrieval (POD), the first serum β-hCG test result was received at concentration 39.5 mIU/mL. After this result, periodically performed serum β-hCG tests showed a steadily increasing serum β-hCG level: on POD 17 serum β-hCG test result was 154 mIU/mL, on POD 19 – 367 mIU/mL, on POD 21 – 912 mIU/mL. The normal gestational sac at 5 weeks and 3 days was confirmed by ultrasound examination. During the first pregnancy trimester, the woman was followed up in VUHSK OGC SFC with regular ultrasound examinations, treatment correction, and consultations.

![Figure 2. Embryo development and blastomere biopsy. A – 3 day embryo No 1, 4 cell stage; B – 3 day embryo No 2, 6 cell stage; C – 3 day embryo No 3, 3 cell stage; D 3 day embryo No 4, 4-5 cell stage; E – laser assisted single blastomere biopsy; F – 5 day poor quality blastocyst from embryo No 2 transferred to the uterus.](image)

![Figure 3. The report visualisation of the PGT-SR analysis of the Next Generation Sequencing on the Ion PGM™ System using The Ion ReproSeq™ PGS View Kits of the 2nd embryo. The embryo was diploid with a 46,XX karyotype.](image)
Gestational diabetes was diagnosed at 12 weeks of pregnancy; the special meal plan and regular physical activity were prescribed. Every month, the pregnant woman was consulted by a perinatologist and endocrinologist. The management of gestational diabetes was effective. At 38 weeks of pregnancy due to prelabour rupture of membranes, the women was admitted to the obstetrical department. There was a vaginal birth of a healthy girl with a weight of 2820 g. The Apgar score was 10/10. All screening tests of the new-born were in normal range. On the fourth postpartum day the mother and healthy new-born were discharged from the hospital.

Discussion

This case report showed that PGT procedures could be successfully implemented by the multidisciplinary team working in close relation and coordination during the all process. First of all, it is worth mentioning, that karyotype and Y-chromosome analysis should be offered to all men with nonobstructive azoospermia or severe oligospermia (<5×10⁶/mL) before performing ICSI with their sperm, because they are at increased risk of having a definable genetic abnormality [Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Male Reproduction and Urology. Fertil Steril. 2008 Nov; 90(5 Suppl):S121-4.]. This case report clearly confirmed the recommendation. According to genetic testing, the infertility treatment plan for the couple was significantly adjusted with inclusion of the PGT procedure, which gave an opportunity to successfully conceive after 4 years of attempting to get this. Also, from the gynaecological view, one of the most important step was to choose an appropriately controlled ovarian hyperstimulation protocol and stimulation dose, especially for the prediction of probable poor ovarian response [11, 12] and in the absence of the previous ovarian stimulation for the woman. Some researchers suggest that most young patients reached embryo transfer with one to seven oocytes with a good outcome [13]. On the other hand, it is known that affected embryos and uninterpreted embryos decrease significantly the number of suitable embryos for IVF/ICSI/PGT transfer by 25–75% [13]. Under these circumstances, a GnRH antagonist protocol and higher stimulation dose was chosen.

From the embryologist point of view, it is very important to choose the right day of the embryo biopsy. It is possible to do a biopsy from day 2 (single blastomere) till day 5 (several cells of trophoectoderm biopsy). Different laboratories use different methods for the embryo biopsy. In this case, we performed the biopsy on day 4 of the embryo development in vitro: firstly, due to the slow embryo development, and secondly, in order to have enough time to perform the PGT and transfer the fresh embryo on day 5. Today in the world of assisted reproductive technologies and PGT, more and more microinvasive (aspiration of blastocellc cavity) or noninvasive methods of embryo testing (circulated embryo DNA) are developed and implemented in the quotidian work of ART laboratories [14]. And finally – the experience of the genetic laboratory – another important issue in the process of genetic embryo testing. It is very important to choose the right methods for the couple's embryo investigation to achieve the best result.

During the woman's pregnancy after IVF/ICSI/PGT, another new and very important experience was serum β-hCG level monitoring and interpretation. The amount of serum β-hCG in culture media secreted by the blastocysts after biopsy is adversely proportional to the number of trophectoderm cells removed [15, 16]. However, there is a lack of studies on serum β-hCG levels in early pregnancy after the PGD procedure, especially after a blastomere biopsy. We found only one study comparing the mean serum β-hCG concentration between PGT patients (n=129) and age-matched patients who underwent ICSI (n=1161) [17]. The mean serum β-hCG concentration of the PGT group was significantly lower than that of the control group on POD 12, 14 and 21 (37.9 mIU/mL vs 46.9 mIU/mL, 111.3 mIU/mL vs 145.4 mIU/mL, 2225.0 mIU/mL vs 3614.0 mIU/mL) with the lower cut-off-
value of serum β-hCG for predicting a single viable pregnancy of the PGT group on POD 12 and on POD 14 (32.5 mIU/mL and 77.0 mIU/mL) comparing with the control group. The doubling time of serum β-hCG at each time interval showed no significant difference between groups. According to these results, researchers suggested that blastomere biopsy may decrease the β-hCG producing activity of the trophoblasts. In our case, the report of the initial serum β-hCG level, its mean value and doubling time, confirmed this data and supported the demand to set a lower cut-off value of serum β-hCG for predicting pregnancy outcomes and further adequate evaluation in the PGT group.

Take-home message

The PGT is the only procedure which allows for the identification of genetic abnormalities and for selecting the embryos with balanced karyotype to transfer. In many countries, PGT has become an established reproductive option for people at high risk of having a child affected with a genetic disorder or handicap [18]. PGT is still somewhat controversial in a moral level, indications, and the policy of transferring an affected embryo or uninterpreted embryo, but this method provides a fairly good opportunity for a couple with genetic risk factors to successfully conceive and carry a pregnancy while avoiding the difficult decision of abortion.

Conclusion

The IVF/ICSI/PGT procedure was successfully implemented at VUHSK and the first baby undergoing this procedure in Lithuania was born in 2019: a vaginal birth of a healthy girl with a gestational age of 38 weeks and 4 days and a weight of 2820 g was the result; the Apgar score was 10/10.

Acknowledgements

- Laima Ambrozaitytė – team advising during PGT analysis in the laboratory for Molecular Genetics and Cytogenetics, manuscript revision;
- Danutė Lištvanienė, Romoaldas Juršėnas – Obstetricians Gynecologists for the pregnancy follow up and delivery management;
- Adelė Gudlevičiūtė – student of Vilnius University Faculty of Medicine for data collection from medical reports and photos from laboratory processing.

Author Contributions

- Živilė Gudlevičienė – men sperm analysis and diagnosis, oocytes collection, ICSI performing, embryo cultivation, blastomere biopsy and picturing, main manuscript idea and preparation;
- Raminta Baušytė – couple investigation, hormonal stimulation, ovarian puncture and embryo transfer, pregnancy follow up for the first trimester, manuscript preparation;
- Evelina Dagytė – genetic counselling of the couple, karyotype analysis, manuscript preparation;
- Danutė Balkeliene – genetic analysis of the blastomeres, PGT analysis in the laboratory for Molecular genetics and Cytogenetics, manuscript preparation;
- Algirdas Utkus – manuscript revision;
- Diana Ramašauskaitė – pregnancy follow up till baby birth, manuscript preparation.

Conflicts of Interest

Availability of data and materials. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate. All procedures performed on patients and described in the case report were in accordance with the ethical standards of the VUHSK, the signed patients' permission to use the case for the reports and publication was obtained before publication.

References:
1. Zegers-Hochschild F, Adamson D, Dyer S et al. The International Glossary on Infertility and Fertility Care, 2017. Hum Reprod. 2017;32(9):1786-1801.
2. Parikh FR, Athalye AS, Naik NJ et al. Preimplantation Genetic Testing: Its Evolution, Where Are We Today? J Hum Reprod Sci. 2018;11(4):306-314. https://doi.org/10.4103/jhrs.jhrs_132_18
3. ESHRE PGT Consortium Steering Committee, et al. ESHRE PGT Consortium good practice recommendations for the organisation of PGT. Hum Reprod Open. 2020. PMID: 32524036.
4. ESHRE PGT-M Working Group, et al. ESHRE PGT Consortium good practice recommendations for the detection of monogenic disorders. Hum Reprod Open. 2020. PMID: 32500103.
5. ESHRE PGT-SR/PGT-A Working Group, et al. ESHRE PGT Consortium good practice recommendations for the detection of structural and numerical chromosomal aberrations. Hum Reprod Open. 2020. PMID: 32500102.
6. Goldman RH, Racowsky C, Farland LV et al. The cost of a euploid embryo identified from preimplantation genetic testing for aneuploidy (PGT-A): a counseling tool. J Assist Reprod Genet. 2018 ;35(9):1641-1650. https://doi.org/10.1007/s10815-018-1275-5
7. Shao YH, Zhang XY, Buckett W, Ao A. Impact of in vitro fertilization-preimplantation genetic testing (IVF-PGT) funding policy on clinical outcome: An issue that stems beyond effectiveness of treatment. Eur J Obstet Gynecol Reprod Biol. 2019;235:1-5. https://doi.org/10.1016/j.ejogrb.2019.01.007
8. Levkov L and Janickienė RV. Methods of Assisted Reproduction Treatment (Lith. Pagalbiniai nevaisingumo gydymo metodai. Mokomoji knyga). Vitae Litera, Kaunas, Lithuania, 2003, pp. 114.
9. Manual on Basic Semen Analysis. WHO Laboratory Manual. WHO 2002. p. 38.;
10. WHO Laboratory Manual for Examination and Processing of Human Semen. WHO 2010. p. 286.
11. Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Male Reproduction and Urology. The management of infertility due to obstructive azoospermia. Fertil Steril. 2008 Nov;90(5 Suppl):S121-4.
12. Ferraretti AP, Marca AL, Fauser BCJM et. al. ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616-24. https://doi.org/10.1093/humrep/der092
13. Tur-Kaspa I. Clinical management of in vitro fertilization with preimplantation genetic diagnosis. Semin Reprod Med. 2012 Aug;30(4):309-22. https://doi.org/10.1055/s-0032-1313910
14. Chen HF, Chen SU, Ma GC et al. Preimplantation genetic diagnosis and screening: Current status and future challenges. J Formos Med Assoc. 2018;117(2):94-100.
15. Dokras A, Sargent IL, Gardner RL, Barlow DH. Human trophectoderm biopsy and secretion of choriionic gondotrophin. Hum Reprod. 1991 Nov;6(10):1453-9. https://doi.org/10.1093/oxfordjournals.humrep.a137288
16. Paiva P, Hannan NJ, Hincks C et al.. Human choriomic gonadotrophin regulates FGF2 and other cytokines produced by human endometrial epithelial cells, providing a mechanism for enhancing endometrial receptivity. Hum Reprod. 2011 May;26(5):1153-62. https://doi.org/10.1093/humrep/der027
17. Cho YJ, Kim JY, Song IO et al. Does blastomere biopsy in preimplantation genetic diagnosis affect early serum β-hCG levels?. Clin Exp Reprod Med. 2011;38(1):31-36. https://doi.org/10.5653/cerm.2011.38.1.31
18. De Wert G, Dondorp W, Shenfield F et al. ESHRE task force on ethics and Law22: preimplantation genetic diagnosis. Hum Reprod. 2014;29(8):1610-1617. https://doi.org/10.1093/humrep/deu132